Last checked at 11 Jul 2013 07:00
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 June 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2013 was 10.63 pence per share, including un-invested cash of £707,624. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a decrease of 5.3% from the previous valuation of 11.22 pence per share, which included un-invested cash of £287,310. However, the combined value of investments and cash at £3.625 million represents a fall of only 2.6% on the same value last period. The revenue reserve at £0.84 million still represents a return of over 33.3% on investments after listing and operating costs."
| Unaudited to 30 June 2013 £ | |
Fixed Assets |
|
|
| Investments
| 2,916,930 |
Current Assets |
|
|
| Debtors: amounts owing | 7,797 |
| Un-invested cash
| 707,624 |
Current Liabilities |
|
|
| Creditors: amounts due
| (32,400) |
|
| 3,599,951 |
Capital and Reserves |
|
|
| Share Capital | 34 |
| Share Premium | 2,759,551 |
| Current year's earnings | 415,158 |
| Retained earnings
| 425,208 |
| 3,599,951 | |
| ||
Shares in Issue
| 33,864,836 | |
Net Asset Value per share
| 10.63 pence |
--- ENDS ---
Portfolio Details
Investments Schedule at 30 June 2013 | £ Valuation | Portfolio % |
Synergy Pharmaceuticals Inc. | 277,748 | 9.52% |
Summit Corporation plc | 212,500 | 7.29% |
Arrowhead Research | 207,364 | 7.11% |
Plethora Solutions Holdings plc | 166,625 | 5.71% |
TrovaGene Inc. | 137,224 | 4.70% |
Pfizer Inc. | 136,562 | 4.68% |
Nektar Therapeutics | 127,303 | 4.36% |
Sanofi-ADR | 91,349 | 3.13% |
1,356,675 | 46.51% | |
Aggregate value of remaining holdings below 3% of total portfolio | 1,560,255 | 53.49% |
TOTAL INVESTMENTS | 2,916,930 | 100.00% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 203 697 9495 | Jon Levinson +44 207 469 0935 |